By Denny JacobJohnson & Johnson's application for Tecvayli was approved by the U.S. Food and Drug Administration. The healthcare company said the FDA approved its supplemental biologics license application for a reduced dosing frequency of 1.5 mg/kg every two weeks in patients with relapsed or refractory multiple myeloma who have achieved and maintained a complete response or better for a minimum of six months. Write to Denny Jacob at denny.jacob@wsj.com(END) Dow Jones NewswiresFebruary 20, 2024 16:59 ET (21:59 GMT)Copyright (c) 2024 Dow Jones & Company, Inc.

Source: Wall Street Journal February 20, 2024 22:12 UTC